Guardian Pharmacy Services, Inc. (NYSE:GRDN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $42.8333.

Several equities research analysts have issued reports on GRDN shares. Weiss Ratings downgraded shares of Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Bank of America raised their target price on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Oppenheimer lifted their target price on shares of Guardian Pharmacy Services from $38.00 to $43.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Truist Financial upped their price target on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Finally, Wall Street Zen downgraded Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a report on Saturday.

Guardian Pharmacy Services Stock Performance

Shares of NYSE:GRDN opened at $39.43 on Friday. Guardian Pharmacy Services has a 1 year low of $19.30 and a 1 year high of $44.00. The stock has a market capitalization of $1.96 billion, a P/E ratio of 47.50, a PEG ratio of 2.59 and a beta of 0.05. The stock has a 50-day simple moving average of $40.72 and a 200-day simple moving average of $36.71.

Guardian Pharmacy Services (NYSE:GRDN) last posted its earnings results on Wednesday, May 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. Guardian Pharmacy Services had a net margin of 3.64% and a return on equity of 30.72%. The firm had revenue of $336.60 million during the quarter, compared to the consensus estimate of $329.89 million. During the same quarter in the prior year, the company earned $0.22 EPS. The company’s revenue was up 2.2% on a year-over-year basis. Analysts predict that Guardian Pharmacy Services will post 1.18 earnings per share for the current year.

Hedge Funds Weigh In On Guardian Pharmacy Services

A number of institutional investors and hedge funds have recently bought and sold shares of GRDN. Dynamic Technology Lab Private Ltd acquired a new stake in Guardian Pharmacy Services in the first quarter valued at approximately $233,000. JPMorgan Chase & Co. lifted its position in shares of Guardian Pharmacy Services by 48.0% during the second quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock worth $128,000 after purchasing an additional 1,956 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Guardian Pharmacy Services by 1,783.1% during the second quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock worth $317,000 after purchasing an additional 14,104 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Guardian Pharmacy Services by 121.1% in the second quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock valued at $345,000 after purchasing an additional 8,860 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Guardian Pharmacy Services in the second quarter valued at $214,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.